New York City, NY -- (SBWIRE) -- 01/27/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Dynavax Technologies Corporation (NASDAQ:DVAX), Novavax, Inc. (NASDAQ:NVAX), Geron Corporation (NASDAQ:GERN), Cell Therapeutics Inc (NASDAQ:CTIC)
Dynavax Technologies Corporation (NASDAQ:DVAX) declined -6.45% recently, while trading on 4.75 million shares, at the price of $1.74. The stock changed hands in a range of $1.47 to $1.86 up till now, bringing its market capitalization at about $456.97 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.98 and was moved to the maximum level of $3.33. Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases. Its product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than licensed vaccines.
Will DVAX Get Buyers Even After The Recent Rally? Find Out Here
Novavax, Inc. (NASDAQ:NVAX) declined -10.24% recently, in the current trading session, at $5.60 with a total volume of 4.39 million shares. The stock, on average, trades on a volume of 6.03 million shares. It floated in a range of $5.33 to $6.15 during the recent trading session, with a beta value of 2.44. Its market capitalization now moved to about $1.17 billion. In the past 52 weeks, the share price has not declined below $1.68 or above $6.49. Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs).
Will NVAX Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Geron Corporation (NASDAQ:GERN) recently recorded a fall of -17.71% and was moving within a range of $4.50-$5.15, its current trading price is $4.62. The stock is moving up till now with a total volume of 6.25 million shares, versus an average volume of 4.74 million shares. The share price hit its 52-week low of $0.98 and $7.79 was the best price. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase.
Is it the Right to Grab GERN after the Recent Slump? Get Free Trend Analysis Here
Cell Therapeutics Inc (NASDAQ:CTIC) declined -20% in its current trading activity, bringing its market capitalization around $482.42 million. The share price, after opening at $3.79, hit a high of $3.81 and hovered above $3.03, while its recent trading price was $3.21. The total number of shares changed hands during the current session up till now was 8.40 million shares, as compared to average trading volume of 5.96 million shares. Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need.
Will CTIC Reach the Bottom after Yesterday’s Correction? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)